Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants

Learn more about:
Related Clinical Trial
Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen Aminoglycosides and Duct Radiation-Free Heart Catheterization Using MRI Hemodynamic Responses to Cardio-respiratory Events in Preterm Infants Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease The Preterm Infants’ Paracetamol Study Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Evaluation of the Brain and Renal Regional Oxygenation Using NIRS in Preterm Infants Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD Hyperion™ International Registry Trial NIRS in PDA VLBW Infants Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants The Impact of Platelet Functions on Spontaneous Ductal Closure in Preterm Infants Lifetech CeraFlex™ Post-Market Surveillance Study Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications Nit-Occlud PDA Post-Approval Study Ibuprofen and Renal Function in Premature Infants A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation Canadian National PDA Treatment Study Long Term Results of 450 Percutaneous Closures of PDA in a Single Center Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants AMPLATZER Duct Occluder II Additional Sizes A NEW SCORING SYSTEM FOR PREDICTION OF PDA Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants The Efficacy of Implementing a Treatment Algorithm in Managing Patent Ductus Arteriosus (PDA) in the Extremely Low Birth Weight Neonatal Population. Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA) Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA Addition of Acetaminophen in Standard PDA Management Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Paracetamol Versus Ibuprofen for PDA Closure Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants Early Treatment Versus Expectative Management of PDA in Preterm Infants International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants Do Elevated BNP Levels Predict Hemodynamically Significant PDAs The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants Brain, Gut and Kidney Blood Flow During Medical Closure of PDA Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term AMPLATZER Duct Occluder II Clinical Study The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth Paracetamol and Patent Ductus Arteriosus (PDA) Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure Pocket Echocardiography System (PES) for Detection of PDA in Neonates Treating the Resistant Patent Ductus Arteriosus (PDA) Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus IV Acetaminophen and Patent Ductus Arteriosus Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI) Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants Patent Ductus Arteriosus and Splanchnic Oxygenation at First Feed Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus. Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus

Brief Title

Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants

Official Title

The Role of Nitric Oxide, Endothelin-1, and Inflammatory Mediators in the Patency of Ductus Arteriosus in Preterm Infants

Brief Summary

      BACKGROUND Patent ductus arteriosus (PDA) is a frequent clinical event in preterm infant. The
      cardiopulmonary functions of these preterm babies may be adversely affected by the patency of
      ductus arteriosus. Ductal tissues are sensitive to the constricting effect of endothelin-1
      and the dilating effect of prostaglandins, inflammatory mediators, and concentration of
      oxygen.

      OBJECTIVE To examine the role of endogenous nitric oxide (NO) and endothelin-1 (ET-1) in the
      pathogenesis of patent ductus arteriosus of the preterm infants. We hypothesize that the
      patency of ductus arterious in preterm infants is probably due to inappropriate production of
      endogenous nitric oxide and the interaction with various inflammatory mediators and
      prostaglandins, which is different from those of term infants. In addition, the secretion of
      endothelin is probably decreased. The purpose of this study is to monitor the changes of
      these substance sequentially, and to evaluate the relationship among endothelin-1, endogenous
      nitric oxide, and inflammatory mediators in the pathophysiology of patent ductus arteriosus
      in preterm infants.

      METHODS AND MATERIALS

        1. Inclusion criteria:

             1. Preterm infants with gestational age less than 32 weeks or birth weight less than
                2000 gm.

             2. Informed consent

        2. Numbers of study population:

           With 80-100 evaluable infants (40-50 patients in PDA and non-PDA groups, respectively)

        3. Blood sample, collecting on day 1,3,7 after regular echocardiographic evaluation, is
           assessed for inflammatory mediator (IL-8, IL-10), nitric oxide metabolites (nitrite and
           nitrate), endothelin-1, and cGMP

        4. Statistical analysis: Student t-test testing the differences of clinical data, Wilcoxon
           signed rank test for comparing data obtained between the PDA and non-PDA patients, the
           PDA patients before and after intravenous indomethacin, and those who are responsive or
           refractory to the therapy.
    



Study Type

Observational




Condition

Patent Ductus Arteriosus



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

80

Start Date

January 2002

Completion Date

December 2002


Eligibility Criteria

        Inclusion Criteria:

          -  Clinical diagnosis of the patency of ductus arteriosus

        Exclusion Criteria:

          -  Congenital anomalies
      

Gender

All

Ages

N/A - 1 Year

Accepts Healthy Volunteers

No

Contacts

Wu Shiun Hsieh, M.D, , 



Administrative Informations


NCT ID

NCT00162903

Organization ID

26955



Study Sponsor

National Taiwan University Hospital


Study Sponsor

Wu Shiun Hsieh, M.D, Study Director, National Taiwan University Hospital


Verification Date

October 2001